Federal Register / Vol. 62, No. 6 / Thursday, January 9, 1997 / Notices 1337

as well as summaries of the meeting and a

roster of committee members may be

obtained from James Scanlon, NCVHS

Executive Staff Director, Office of the

Assistant Secretary for Planning and

Evaluation, DHHS, Room 444–D. Humphrey

Building, 200 Independence Avenue S.W.,

Washington, D.C. 20201, telephone (202)

690–7100, or Marjorie S. Greenberg, Acting

Executive Secretary, NCVHS, NCHS, CDC,

Room 1100, Presidential Building, 6525

Belcrest Road, Hyattsville, Maryland 20782,

telephone (301) 436–7050. Information also

is available on the NCVHS homepage: http:/

/aspe.os.dhhs.gov/ncvhs/index.htm.

Dated: January 2, 1997.

James Scanlon,

Director, Division of Data Policy, Office of

the Assistant Secretary for Planning and

Evaluation.

[FR Doc. 97–434 Filed 1–8–97; 8:45 am]

BILLING CODE 4151–04–M

Centers for Disease Control and

Prevention

Epidemiology Program Office, Office of

the Director, Centers for Disease

Control and Prevention (CDC), Notice

of Meeting

Name: Guide to Community Preventive

Services Task Force Meeting.

Times and Dates: 8:30 a.m.–5 p.m., January

27, 1997; 8:30 a.m.–5 p.m., January 28, 1997.

Place: Terrace Garden Inn, 3405 Lenox

Road, NE, Atlanta, Georgia 30326.

Status: Open to the public, limited only by

the space available.

Purpose: The mission of the Task Force is

to develop and publish a Guide to

Community Preventive Services, which is

based on the best available scientific

evidence and current expertise regarding

essential public health services and what

works in the delivery of those services. The

primary purpose of this second meeting is to

continue in the development of a shared

vision for the Guide; review and assess the

methods used in the initial development of

the first two chapters; and to select

additional topics to be included in the Guide.

Matters to be Discussed: Agenda items

include the definition of ‘‘community’’ for

the Guide; defining target audiences of the

Guide; process for selection of topics to be

included in the Guide; updates on current

chapters in progress: the prevention of (a)

motor vehicle injuries and (b) vaccine

preventable diseases; and selection of new

topics for upcoming chapters.

Agenda items are subject to change as

priorities dictate.

FOR ADDITIONAL INFORMATION

CONTACT: Marguerite Pappaioanou, Chief,

Community Preventive Service Guide

Development Activity, Division of Prevention

Research and Analytic Methods,

Epidemiology Program Office, CDC, 1600

Clifton Road, NE, M/S D–01, Atlanta, Georgia

30333, telephone 404/639–4301.

Persons wishing to reserve a space for this

meeting should call 404/639–4311 by close of

business on January 21, 1997.

Dated: January 3, 1997.

Joseph E. Salter

Acting Director, Management Analysis and

Services Office, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 97–467 Filed 1–8–97; 8:45 am]

BILLING CODE 4163–18–P

National Center for Environmental

Health (NCEH) of the Centers for

Disease Control and Prevention (CDC);

Notice of Meeting

Name: Translating Advances in Genetics

into Public Health Action.

Times and Dates: 10 a.m.–5:30 p.m.,

January 27, 1997; 8 a.m.–3 p.m., January 28,

1997.

Place: Terrace Garden Hotel, 3405 Lenox

Road, NE, Atlanta, Georgia 30326.

Status: Open to the public, limited only by

the space available.

Purpose: CDC has established a Task Force

on Genetics in Disease Prevention to: (1)

develop a strategic plan for CDC-wide

genetics programs, (2) coordinate and

support program efforts, and (3) convene

constituents and consultants for their

individual advice on strategic planning,

priorities for CDC activities, and policy

development. This Task Force was formed in

October, and is in the process of collecting

and summarizing information about CDC

efforts related to genetics that will be used

during strategic planning.

This meeting will enable invited

participants (individuals from academia,

public health, professional organizations,

consumer groups, and industry) to provide

input and discuss strategic planning issues

and needs associated with the translation of

advances in genetics into public health

action. Information gained from this meeting

will be considered, along with that

previously received, in drafting strategic

planning documents. These documents will

then be distributed for further comment.

Matters to be Discussed: Agenda items

include discussions on population-based

assessment functions, development of public

health policies and guidelines, quality

assurance and prevention effectiveness

functions, and needs for professional

education and information dissemination

efforts.

Agenda items are subject to change as

priorities dictate.

FOR FURTHER INFORMATION

CONTACT: Dometa Williams, Genetics Task

Force, NCEH, CDC, 4770 Buford Highway,

NE, Atlanta, Georgia 30341, telephone 770/

488–7120, FAX 770/488–7197.

Dated: January 3, 1997.

Joseph E. Salter,

Acting Director, Management Analysis and

Services Office, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 97–460 Filed 1–8–97; 8:45 am]

BILLING CODE 4163–18–P

Food and Drug Administration

[Docket No. 97N–0003]

Hoffman-LaRoche, Inc., et al.;

Withdrawal of Approval of 11 New

Drug Applications, 1 Abbreviated

Antibiotic Application, and 20

Abbreviated New Drug Applications

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is withdrawing

approval of 11 new drug applications

(NDA’s), 1 abbreviated antibiotic

application (AADA), and 20 abbreviated

new drug applications (ANDA’s). The

holders of the applications notified the

agency in writing that the drug products

were no longer marketed and requested

that the approval of the applications be

withdrawn.

EFFECTIVE DATE: February 10, 1997.

FOR FURTHER INFORMATION CONTACT:

Olivia A. Vieira, Center for Drug

Evaluation and Research (HFD–7), Food

and Drug Administration, 7500 Standish

Pl., Rockville, MD 20855, 301–594–

1046.

SUPPLEMENTARY INFORMATION: The

holders of the applications listed in the

table in this document have informed

FDA that these drug products are no

longer marketed and have requested that

FDA withdraw approval of the

applications. The applicants have also,

by their request, waived their

opportunity for a hearing.

Application no. Drug Applicant

NDA 6–525 ................. Gantrisin (sulfisoxazole) Tablets ......................................... Hoffman-La Roche, Inc., 340 Kingsland St., Bldg. 719–4,

Nutley, NJ 07110.

NDA 12–486 ............... Taractan (chlorprothixene) Tablets ...................................... Do.

NDA 12–772 ............... Haldrone (paramethasone acetate) Tablets ........................ Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN

46285.